Pearce N W, Spinelli A, Gurley K E, Dorsch S E, Hall B M
Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
J Immunol. 1989 Jul 15;143(2):499-506.
In DA rats grafted with PVG hearts, the injection of 1 ml of Wistar-Furth x DA)F1 anti-PVG serum on the day of grafting prevents rejection and induces a state of specific unresponsiveness. An adoptive transfer assay was used to test the capacity of T cell subsets, taken from rats given enhancing serum, to either restore rejection or to transfer unresponsiveness to syngeneic hosts irradiated with 9 Gy and grafted with donor (PVG) or third party (Wistar-Furth) hearts. W3/25+ (CD4+) cells from these animals retained some capacity to restore rejection until 50 days posttransplant, after which they invariably failed to restore PVG graft rejection but retained the capacity to effect Wistar-Furth rejection. At this time CD4+ cells were also capable of inhibiting naive but not specifically sensitized CD4+ cells capacity to restore PVG graft rejection in irradiated hosts. The development of CD4+ suppressor cells was concurrent with the appearance of clinically evident unresponsiveness in the host. MRC Ox8+ (CD8+) cells from enhanced rats when mixed with naive CD4+ cells delayed rejection in adoptive recipients but did not reestablish unresponsiveness. Paradoxically, the CD4+ cells that transfer unresponsiveness to the adoptive host proliferate such as normal cells in MLC to both donor and third party alloantigen. Unfractionated cells, CD4+ or CD8+ cells did not proliferate to relevant idiotype in vitro. The CD4+ cells after 3 days in culture, with either alloantigen or idiotype-bearing stimulator cells, lost their capacity to suppress in the adoptive transfer assay. The maintenance of specific unresponsiveness was thus shown to be due to a CD4+ suppressor T cell whose function was lost in culture, and therefore could not be detected in MLC or idiotype assays.
在移植了PVG心脏的DA大鼠中,移植当天注射1毫升Wistar-Furth×DA)F1抗PVG血清可防止排斥反应,并诱导特异性无反应状态。采用过继转移试验来测试从给予增强血清的大鼠中获取的T细胞亚群恢复排斥反应或向接受9 Gy照射并移植了供体(PVG)或第三方(Wistar-Furth)心脏的同基因宿主转移无反应性的能力。这些动物的W3/25 +(CD4 +)细胞在移植后50天内一直保留着一定的恢复排斥反应的能力,此后它们始终无法恢复PVG移植物排斥反应,但仍保留着引发Wistar-Furth排斥反应的能力。此时,CD4 +细胞还能够抑制未致敏但非特异性致敏的CD4 +细胞在受照射宿主中恢复PVG移植物排斥反应的能力。CD4 +抑制性细胞的发育与宿主临床上明显的无反应状态的出现同时发生。来自增强大鼠的MRC Ox8 +(CD8 +)细胞与未致敏的CD4 +细胞混合时,可延迟过继受体中的排斥反应,但不会重建无反应状态。矛盾的是,向过继宿主转移无反应性的CD4 +细胞在混合淋巴细胞培养中像正常细胞一样对供体和第三方同种异体抗原增殖。未分离的细胞、CD4 +或CD8 +细胞在体外对相关独特型均不增殖。培养3天后的CD4 +细胞,无论是与同种异体抗原还是带有独特型的刺激细胞一起培养,在过继转移试验中都会失去其抑制能力。因此,特异性无反应状态的维持被证明是由于一种CD4 +抑制性T细胞,其功能在培养中丧失,因此在混合淋巴细胞培养或独特型试验中无法检测到。